Martínez-García Sarah Melania, Hernández-Da Mota Sergio Eustolio, Rubio-Rangel Araceli, Rojas-Flores Ignacio, Vieyra-López Mayra Edith, Martínez-Castellanos María Ana, Zavala-Martínez María Teresa, Gómez García Anel
Unidad de Medicina Familiar Número 80, IMSS, Morelia, Michoacán, México.
Servicio de Retina, Unidad Oftalmológica, Clínica David, Morelia, Michoacán, México.
Cir Cir. 2017 Nov-Dec;85(6):478-484. doi: 10.1016/j.circir.2016.10.031. Epub 2017 Jan 19.
Retinopathy of prematurity (ROP) is an eye disease caused by an alteration in retinal vasculogenesis that may lead to partial or complete vision loss with a harmful impact in terms of neurodevelopment. The purpose of the present study was to determine the neurodevelopment in patients with type i retinopathy of prematurity treated with intravitreal bevacizumab.
Case series. The inclusion criteria were: patients with type I ROP treated with a dose of 0.625mg/0.025ml of intravitreal bevacizumab. Demographic data and comorbidities were documented. Neurodevelopment was evaluated with the screening test of the Bayley Scale of Infant Development (BSID) in all patients between 11 and 28 weeks of age.
Seven patients were included in the study. Four patients showed normal neurodevelopment according to the overall scores of the BSID scale. The distribution of high risk for neurodevelopmental delay in the different areas evaluated were as follows: 3 patients presented it in the cognitive area, one in the receptive communication area, one in the expressive area, one in the fine motor skills and 3 patients in the gross motor skills area.
In these case series, the majority of patients treated with intravitreal bevacizumab for ROP showed normal neurodevelopment scores.
早产儿视网膜病变（ROP）是一种由视网膜血管生成改变引起的眼部疾病，可能导致部分或完全视力丧失，对神经发育产生有害影响。本研究的目的是确定接受玻璃体内注射贝伐单抗治疗的I型早产儿视网膜病变患者的神经发育情况。
病例系列研究。纳入标准为：接受剂量为0.625mg/0.025ml玻璃体内贝伐单抗治疗的I型ROP患者。记录人口统计学数据和合并症。对所有年龄在11至28周的患者，使用贝利婴儿发育量表（BSID）筛查测试评估神经发育情况。
7名患者纳入研究。根据BSID量表的总体评分，4名患者神经发育正常。在评估的不同领域中，神经发育延迟高风险的分布如下：3名患者在认知领域出现，1名在接受性交流领域，1名在表达领域，1名在精细运动技能领域，3名在大运动技能领域。
在这些病例系列中，大多数接受玻璃体内贝伐单抗治疗ROP的患者神经发育评分正常。
